Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGARO-DKD: Finerenone in Diabetic Kidney Disease
NCT02545049Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2015
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 48
01
Overview
Phase 3, randomised, double-blind trial in diabetic kidney disease (DKD) comparing Finerenone with Placebo (2 arms). Primary endpoint: Composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure at 41 months. Started Sep 2015; status: completed.
02
Drugs
finerenone
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT02545049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545049.